Needham Reiterates Buy on Ocular Therapeutix, Maintains $18 Price Target

Benzinga · 2d ago
Needham analyst Serge Belanger reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy and maintains $18 price target.